Skip to Main Content

Paper Details

Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation.
Cancer Cell
85
2020
730 genes, AR, CHD1, Chromatin, Metastatic prostate cancer, NR2F1, NR3C1, POU3F2, RNA, TBX2, antiandrogen, chromatin, non, open, prostate cancer, shRNA, small hairpin RNA
Author NameAffiliation
Zhigang ZhangMemorial Sloan Kettering Cancer Center
Robert N HooverMemorial Sloan Kettering Cancer Center
Robert N HooverMemorial Sloan Kettering Cancer Center
Yanxiao ZhangLudwig Institute for Cancer Research
Christopher E MasonUSA The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine
Christopher E MasonUSA The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine
Elisa de StanchinaMemorial Sloan Kettering Cancer Center
Wassim AbidaMemorial Sloan Kettering Cancer Center
Venkat S MalladiUT Southwestern Medical Center
Charles L SawyersMemorial Sloan Kettering Cancer Center, USA Howard Hughes Medical Institute
  • 1 - 10

Datasets

Release 1.2